



CODE/NAME & ADDRESS: C000138361

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : 0028WG000025

PATIENT ID : PIYUM05018928

CLIENT PATIENT ID: ABHA NO : AGE/SEX : 34 Years
DRAWN :

RECEIVED : 01/07/2023 09:09:51 REPORTED : 07/07/2023 07:55:22

Test Report Status Final Results Biological Reference Interval Units

į	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECK UP BE	LOW 40 MALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)  METHOD: SPECTROPHOTOMETRY	14.3	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE	4.81	4.5 - 5.5	mil/μL
WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	5.90	4.0 - 10.0	thou/μL
PLATELET COUNT  METHOD: ELECTRICAL IMPEDANCE	150	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD: CALCULATED PARAMETER	43.8	40.0 - 50.0	%
MEAN CORPUSCULAR VOLUME (MCV)  METHOD: DERIVED/COULTER PRINCIPLE	91.2	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)  METHOD: CALCULATED PARAMETER	29.8	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER	32.7	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)  METHOD: DERIVED/COULTER PRINCIPLE	13.9	11.6 - 14.0	%
MENTZER INDEX METHOD: CALCULATED PARAMETER	19.0		
MEAN PLATELET VOLUME (MPV)  METHOD: DERIVED/COULTER PRINCIPLE	12.6 High	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS  METHOD: VCS TECHNOLOGY/ MICROSCOPY	55	40 - 80	%
LYMPHOCYTES	31	20 - 40	%
METHOD: VCS TECHNOLOGY/ MICROSCOPY			
MONOCYTES  METHOD: VCS TECHNOLOGY/ MICROSCOPY	9	2.0 - 10.0	%
EOSINOPHILS	4	1.0 - 6.0	%

Dr. Shyla Goel,M.B.B.S ,DCP





Page 1 Of 20

View Details





Sr.Pathologist

Agilus Diagnostics Ltd. B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax:







**PATIENT NAME: PIYUSH KUMAR** 

CODE/NAME & ADDRESS: C000138361 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 

8800465156

**REF. DOCTOR: SELF** 

ACCESSION NO: 0028WG000025 AGE/SEX :34 Years

PATIENT ID : PIYUM05018928

CLIENT PATIENT ID: RECEIVED: 01/07/2023 09:09:51 ABHA NO REPORTED :07/07/2023 07:55:22

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
METHOD: VCS TECHNOLOGY/ MICROSCOPY			
BASOPHILS	1	0 - 1	%
METHOD: VCS TECHNOLOGY/ MICROSCOPY			
ABSOLUTE NEUTROPHIL COUNT	3.30	2.0 - 7.0	thou/μL
METHOD: CALCULATED PARAMETER			
ABSOLUTE LYMPHOCYTE COUNT	1.80	1.0 - 3.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.50	0.2 - 1.0	thou/µL
METHOD : CALCULATED PARAMETER			.,
ABSOLUTE EOSINOPHIL COUNT	0.24	0.02 - 0.50	thou/µL
METHOD : CALCULATED PARAMETER	· ·	0.02	/ -
ABSOLUTE BASOPHIL COUNT	0.06	0.02 - 0.10	thou/µL
METHOD : CALCULATED PARAMETER	0.00	0.02 0.10	5.15 st, p. =
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.8		
	1.0		
METHOD: CALCULATED PARAMETER			

#### **MORPHOLOGY**

**REMARKS** 

THE PLATELET COUNT HAS BEEN PERFORMED BY VISUAL ASSESSMENT OF THE PERIPHERAL BLOOD SMEAR DUE TO THE PRESENCE OF GIANT PLATELETS AND PLATELET CLUMPS.

EACH PLATELET /FIELD UNDER OIL IMMERSION (100X) WAS TAKEN TO

REPRESENT 10,000 PLATELETS / MICROLITRE OF BLOOD.

REFERENCE: WINTROBE'S CLINICAL HEMATOLOGY, 11TH EDITION

(2004).

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist





Page 2 Of 20



Agilus Diagnostics Ltd. B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax:

CIN - U74899PB1995PLC045956 Email: customercare.noida@agilus.in







**REF. DOCTOR: SELF PATIENT NAME: PIYUSH KUMAR** 

CODE/NAME & ADDRESS: C000138361 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

**DELHI** 

**NEW DELHI 110030** 

8800465156

ACCESSION NO: 0028WG000025

PATIENT ID : PIYUM05018928

CLIENT PATIENT ID: ABHA NO

AGE/SEX DRAWN

RECEIVED: 01/07/2023 09:09:51 REPORTED :07/07/2023 07:55:22

:34 Years

**Test Report Status Biological Reference Interval Final** Results Units

#### HAEMATOLOGY

#### MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

#### **ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD**

E.S.R

0 - 14

mm

METHOD: MODIFIED WESTERGREN METHOD BY AUTOMATED ANALYSER GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE

**BLOOD** 

5.6 Non-diabetic Adult < 5.7 %

Pre-diabetes 5.7 - 6.4

Diabetes diagnosis: > or = 6.5Therapeutic goals: < 7.0 Action suggested: > 8.0

(ADA Guideline 2021)

METHOD: HPLC

HBA1C

ESTIMATED AVERAGE GLUCOSE(EAG)

114.0

< 116.0

mg/dL

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change

## TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.
Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

**Decreased** in: Polycythermia vera, Sickle cell anemia

# LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.3. Identifying patients at increased risk for diabetes (prediabetes).

Page 3 Of 20





Agilus Diagnostics Ltd. B-22, Sector-62 Noida, 201301 Uttar Pradesh, India







CODE/NAME & ADDRESS: C000138361 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 8800465156

ACCESSION NO: 0028WG000025 PATIENT ID

: PIYUM05018928

CLIENT PATIENT ID: ABHA NO

AGE/SEX DRAWN

RECEIVED: 01/07/2023 09:09:51 REPORTED :07/07/2023 07:55:22

:34 Years

**Test Report Status** Results **Biological Reference Interval** <u>Final</u> Units

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- eAG gives an evaluation of blood glucose levels for the last couple of months.
   eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c 46.7

### HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.
  3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

  4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Page 4 Of 20







Agilus Diagnostics Ltd. B-22, Sector-62 Noida, 201301 Uttar Pradesh, India







CODE/NAME & ADDRESS : C000138361 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 

8800465156

ACCESSION NO : 0028WG000025

PATIENT ID : PIYUM05018928

CLIENT PATIENT ID: ABHA NO

AGE/SEX :34 Years DRAWN

RECEIVED: 01/07/2023 09:09:51 REPORTED :07/07/2023 07:55:22

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

### **IMMUNOHAEMATOLOGY**

#### MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

## **ABO GROUP & RH TYPE, EDTA WHOLE BLOOD**

**ABO GROUP** TYPE B

METHOD: COLUMN AGGLUTINATION TECHOLOGY

RH TYPE **POSITIVE** 

METHOD: COLUMN AGGLUTINATION TECHOLOGY

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist



Page 5 Of 20



Agilus Diagnostics Ltd. B-22, Sector-62 Noida, 201301 Uttar Pradesh, India







CODE/NAME & ADDRESS: C000138361 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 

8800465156

ACCESSION NO: 0028WG000025

AGE/SEX : PIYUM05018928

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 01/07/2023 09:09:51 REPORTED :07/07/2023 07:55:22

:34 Years

**Test Report Status** Results Biological Reference Interval Units <u>Final</u>

PATIENT ID

RT	$\cap$ CH	<b>FM1</b>	CTR	v

#### MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 111 High 74 - 106 mg/dL

METHOD: HEXOKINASE

**GLUCOSE, POST-PRANDIAL, PLASMA** 

PPBS(POST PRANDIAL BLOOD SUGAR) 163 High Non-Diabetes mg/dL

70 - 140

METHOD: HEXOKINASE

LIPID PROFILE, SERUM

145 < 200 Desirable CHOLESTEROL, TOTAL mg/dL

200 - 239 Borderline High

>/= 240 High

METHOD: CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

TRIGLYCERIDES 103 < 150 Normal mg/dL

150 - 199 Borderline High

200 - 499 High >/= 500 Very High

METHOD: ENZYMATIC, END POINT

METHOD: DIRECT MEASURE POLYMER-POLYANION

HDL CHOLESTEROL 37 Low < 40 Low mg/dL

>/=60 High

CHOLESTEROL LDL 87 < 100 Optimal

100 - 129

Very High

Near or above optimal

130 - 159 Borderline High 160 - 189 High >/= 190

NON HDL CHOLESTEROL 108 Desirable: Less than 130 mg/dL

> Above Desirable: 130 - 159 Borderline High: 160 - 189

High: 190 - 219 Very high: > or = 220

METHOD: CALCULATED PARAMETER

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist



Page 6 Of 20

Agilus Diagnostics Ltd. B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax:

CIN - U74899PB1995PLC045956 Email: customercare.noida@agilus.in



mg/dL





CODE/NAME & ADDRESS: C000138361 ACCESSION NO: 0028WG000025 AGE/SEX :34 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PIYUM05018928

DRAWN F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 01/07/2023 09:09:51 DELHI

ABHA NO REPORTED :07/07/2023 07:55:22 **NEW DELHI 110030** 8800465156

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
VERY LOW DENSITY LIPOPROTEIN	20.6	Desirable value : mg/dL 10 - 35
CHOL/HDL RATIO	3.9	3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk
LDL/HDL RATIO	2.4 0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	

# Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category		, ,	
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk g	group or recurrent ACS (within 1 year) despite LDL-C < or =	
	50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2 r	najor risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemia	a	
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ		
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary		
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors			
1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use			
2. Family history of p	2. Family history of premature ASCVD 4. High blood pressure		
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug T	r Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)	
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80	
	$\langle OR = 30 \rangle$	$\langle OR = 60 \rangle$			
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or></td></or>	<or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or>	> 30	>60	
Very High Risk	<50	<80	>OR= 50	>OR= 80	
High Risk	<70	<100	>OR= 70	>OR= 100	
Moderate Risk	<100	<130	>OR= 100	>OR= 130	
Low Risk	<100	<130	>OR= 130*	>OR= 160	

<sup>\*</sup>After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist





Page 7 Of 20

CIN - U74899PB1995PLC045956 Email: customercare.noida@agilus.in







CODE/NAME & ADDRESS: C000138361

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

ACCESSION NO : 0028WG000025

PATIENT ID : PIYUM05018928

CLIENT PATIENT ID: ABHA NO : DRAWN :

AGE/SEX

RECEIVED : 01/07/2023 09:09:51 REPORTED :07/07/2023 07:55:22

:34 Years

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units	
LIVER FUNCTION PROFILE, SERUM				
BILIRUBIN, TOTAL  METHOD: DIAZONIUM ION, BLANKED (ROCHE)	0.52	UPTO 1.2	mg/dL	
BILIRUBIN, DIRECT METHOD: DIAZOTIZATION	0.22	0.00 - 0.30	mg/dL	
BILIRUBIN, INDIRECT METHOD: CALCULATED PARAMETER	0.30	0.00 - 0.60	mg/dL	
TOTAL PROTEIN  METHOD: BIURET, SERUM BLANK, ENDPOINT	7.4	6.6 - 8.7	g/dL	
ALBUMIN  METHOD: BROMOCRESOL GREEN	5.0 High	3.97 - 4.94	g/dL	
GLOBULIN	2.4	2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL	
METHOD: CALCULATED PARAMETER				
ALBUMIN/GLOBULIN RATIO  METHOD: CALCULATED PARAMETER	2.1 High	1.0 - 2.0	RATIO	
ASPARTATE AMINOTRANSFERASE(AST/SGOT)  METHOD: UV WITHOUT P5P	23	0 - 40	U/L	
ALANINE AMINOTRANSFERASE (ALT/SGPT)  METHOD: UV WITHOUT P5P	36	0 - 41	U/L	
ALKALINE PHOSPHATASE  METHOD: PNPP, AMP BUFFER-IFCC	79	40 - 129	U/L	
GAMMA GLUTAMYL TRANSFERASE (GGT)  METHOD: G-GLUTAMYL-CARBOXY-NITROANILIDE-IFCC	24	8 - 61	U/L	
LACTATE DEHYDROGENASE  METHOD: L TO P, IFCC	147	135 - 225	U/L	
BLOOD UREA NITROGEN (BUN), SERUM				
BLOOD UREA NITROGEN  METHOD: UREASE - UV	14	6 - 20	mg/dL	
CREATININE, SERUM				
CREATININE  METHOD: ALKALINE PICRATE-KINETIC	0.80	0.70 - 1.20	mg/dL	
BUN/CREAT RATIO				
BUN/CREAT RATIO	17.50 High	5.00 - 15.00		

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist





Page 8 Of 20

View Details





Agilus Diagnostics Ltd. B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax: CIN - U74899PB1995PLC045956

Email: customercare.noida@agilus.in







CODE/NAME & ADDRESS: C000138361

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

ACCESSION NO : 0028WG000025

: PIYUM05018928

ACCESSION NO . 002011 0000023

CLIENT PATIENT ID: ABHA NO :

PATIENT ID

DDAWN .

AGE/SEX

RECEIVED : 01/07/2023 09:09:51 REPORTED :07/07/2023 07:55:22

:34 Years

Test Report Status <u>Final</u>	Results	Biological Reference	e Interval Units
METHOD : CALCULATED PARAMETER  URIC ACID, SERUM			
URIC ACID  METHOD: URICASE, COLORIMETRIC	4.2	3.4 - 7.0	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN  METHOD: BIURET, SERUM BLANK, ENDPOINT	7.4	6.6 - 8.7	g/dL
ALBUMIN, SERUM			
ALBUMIN METHOD: BROMOCRESOL GREEN	5.0 High	3.97 - 4.94	g/dL
GLOBULIN			
GLOBULIN	2.4	2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
METHOD: CALCULATED PARAMETER			
ELECTROLYTES (NA/K/CL), SERU	М		
SODIUM, SERUM METHOD: ISE INDIRECT	138	136 - 145	mmol/L
POTASSIUM, SERUM METHOD: ISE INDIRECT	3.99	3.5 - 5.1	mmol/L
CHLORIDE, SERUM METHOD: ISE INDIRECT	99	98 - 107	mmol/L

# Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.

Dr. Shyla Goel, M.B.B.S, DCP Sr. Pathologist





Page 9 Of 20

View Details





Agilus Diagnostics Ltd. B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax:







CODE/NAME & ADDRESS: C000138361

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156 ACCESSION NO : **0028WG000025** 

PATIENT ID : PIYUM05018928

CLIENT PATIENT ID: ABHA NO : DRAWN :

AGE/SEX

RECEIVED : 01/07/2023 09:09:51

:34 Years

REPORTED :07/07/2023 07:55:22

# Test Report Status <u>Final</u> Results Biological Reference Interval Units

Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.

Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.

Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium-sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim-sulfamethoxazole.

Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.

Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism.

Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.

Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

# Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in:Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

**Decreased in** :Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g. galactosemia), Drugs-insulin, ethanol, propranolol sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

**NOTE:** While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis,sometimes due to a viral infection,ischemia to the liver,chronic hepatitis of the liver circhosis.

hepatitis, obstruction of bile ducts, cirrhosis. **ALP** is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hyperparathyroidism.

in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, billiary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome. Protein-losing enteropathy etc.

**Albumin** is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular

Dr. Shyla Goel, M.B.B.S, DCP



Page 10 Of 20

View Details

View Report

Agilus Diagnostics Ltd. B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax:







**REF. DOCTOR: SELF PATIENT NAME: PIYUSH KUMAR** 

CODE/NAME & ADDRESS: C000138361 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 

8800465156

ACCESSION NO: 0028WG000025

PATIENT ID : PIYUM05018928

CLIENT PATIENT ID: ABHA NO

AGE/SEX DRAWN

RECEIVED: 01/07/2023 09:09:51 REPORTED :07/07/2023 07:55:22

:34 Years

**Test Report Status** Results **Biological Reference Interval** <u>Final</u> Units

permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome **Causes of decreased levels**-Low Zinc intake,OCP,Multiple Sclerosis
TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist



Page 11 Of 20

**PERFORMED AT:** 

Agilus Diagnostics Ltd. B-22, Sector-62 Noida, 201301 Uttar Pradesh, India







Male

PATIENT NAME: PIYUSH KUMAR REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138361

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO : 0028WG000025

. PATIENT ID : PIYUM05018928

CLIENT PATIENT ID: ABHA NO : AGE/SEX : 34 Years

DRAWN :

RECEIVED : 01/07/2023 09:09:51 REPORTED :07/07/2023 07:55:22

Test Report Status <u>Final</u> Results Biological Reference Interval Units

### **CLINICAL PATH - URINALYSIS**

#### MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

#### PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

METHOD : VISUAL

APPEARANCE CLEAR

METHOD: VISUAL

#### CHEMICAL EXAMINATION, URINE

PH 6.0 4.7 - 7.5

METHOD: DOUBLE INDICATOR PRINCIPLE

SPECIFIC GRAVITY 1.015 1.003 - 1.035

METHOD: PKA CHANGE OF PRETREATED POLYELECTROLYTES

PROTEIN NOT DETECTED NOT DETECTED

METHOD: PROTEIN- ERROR INDICATOR

GLUCOSE NOT DETECTED NOT DETECTED

METHOD: OXIDASE-PEROXIDASE REACTION

KETONES NOT DETECTED NOT DETECTED

METHOD: ACETOACETIC REACTION WITH NITROPRUSSIDE

BLOOD NOT DETECTED NOT DETECTED

METHOD: PEROXIDASE-LIKE ACTIVITY OF HEMOGLOBIN

BILIRUBIN NOT DETECTED NOT DETECTED

METHOD: DIAZOTIZATION

UROBILINOGEN NORMAL NORMAL NORMAL

METHOD: MODIFIED EHRLICH REACTION

NITRITE NOT DETECTED NOT DETECTED

METHOD: CONVERTION OF NITRATE TO NITRITE

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

METHOD: ESTERASE HYDROLYSIS ACTIVITY

# MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS NOT DETECTED NOT DETECTED /HPF

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S) 0-1 0-5 /HPF

METHOD: MICROSCOPIC EXAMINATION

EPITHELIAL CELLS 0-1 0-5 /HPF

METHOD: MICROSCOPIC EXAMINATION

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist



Page 12 Of 20

View Details

View Report



Agilus Diagnostics Ltd. B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax:







CODE/NAME & ADDRESS: C000138361

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

ACCESSION NO : 0028WG000025

PATIENT ID : PIYUM05018928

CLIENT PATIENT ID: ABHA NO : AGE/SEX : DRAWN :

RECEIVED : 01/07/2023 09:09:51 REPORTED : 07/07/2023 07:55:22

:34 Years

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CASTS NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

CRYSTALS NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

BACTERIA NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

YEAST NOT DETECTED NOT DETECTED

**REMARKS** 

MICROSCOPIC EXAMINATION DONE ON CENTRIFUGED URINEPLEASE NOTE THAT GRADING OF BACTERIA NEEDS TO BE CO RELATED WITH THE CULTURE IN CASE FOUND SIGNIFICANT CLINICALLY. OCCASIONAL BACTERIA/YEAST CELLS SEEN IN MICROSCOPY CAN BE A PART OF

SURROUNDING SKIN FLORA ALSO.

METHOD : MANUAL

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions		
Proteins	Inflammation or immune illnesses		
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind		
	of kidney impairment		
Glucose	Diabetes or kidney disease		
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst		
Urobilinogen	Liver disease such as hepatitis or cirrhosis		
Blood	Renal or genital disorders/trauma		
Bilirubin	Liver disease		
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary		
	tract infection and glomerular diseases		
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either		
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by		
	genital secretions		
Epithelial cells Urolithiasis, bladder carcinoma or hydronephrosis, ureteric			
	bladder catheters for prolonged periods of time		
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,		
	interaction with Bence-Jones protein		

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist



Page 13 Of 20

View Details

View Report



Agilus Diagnostics Ltd. B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax:







CODE/NAME & ADDRESS: C000138361 ACCESSION NO: 0028WG000025 AGE/SEX :34 Years ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 

8800465156

PATIENT ID : PIYUM05018928

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED : 01/07/2023 09:09:51

REPORTED :07/07/2023 07:55:22

#### **Test Report Status** Results Biological Reference Interval Units <u>Final</u>

Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal
	diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Shyla Goel, M.B.B.S, DCP Sr.Pathologist



Page 14 Of 20





Agilus Diagnostics Ltd. B-22, Sector-62 Noida, 201301 Uttar Pradesh, India







CODE/NAME & ADDRESS: C000138361

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO : 0028WG000025

PATIENT ID : PIYUM05018928

CLIENT PATIENT ID: ABHA NO : AGE/SEX

0.270 - 4.200

RECEIVED : 01/07/2023 09:09:51

:34 Years

REPORTED :07/07/2023 07:55:22

μIU/mL

Test Report Status <u>Final</u> Results Biological Reference Interval Units

#### **SPECIALISED CHEMISTRY - HORMONE**

# MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

# THYROID PANEL, SERUM

TSH (ULTRASENSITIVE)

T3 127.6 80.00 - 200.00 ng/dL

METHOD : ECLIA

T4 7.39 5.10 - 14.10 μg/dL

METHOD : ECLIA

2.620

METHOD : ECLIA

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism

Dr. Shyla Goel, M.B.B.S, DCP Sr. Pathologist





Page 15 Of 20

View Details

View Report



Agilus Diagnostics Ltd. B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fax:







CODE/NAME & ADDRESS: C000138361

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0028WG000025

PATIENT ID : PIYUM05018928

CLIENT PATIENT ID: ABHA NO : AGE/SEX

DRAWN :

:34 Years

RECEIVED : 01/07/2023 09:09:51 REPORTED : 07/07/2023 07:55:22

Test Report Status <u>Final</u> Results Biological Reference Interval Units

8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

Dr. Shyla Goel, M.B.B.S, DCP Sr. Pathologist





Page 16 Of 20

View Details

View Report



Agilus Diagnostics Ltd. B-22, Sector-62 Noida, 201301 Uttar Pradesh, India Tel: 0120-2403338, Fa





Male

**REF. DOCTOR: SELF PATIENT NAME: PIYUSH KUMAR** 

CODE/NAME & ADDRESS: C000138361 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 

8800465156

ACCESSION NO: 0028WG000025

PATIENT ID : PIYUM05018928

CLIENT PATIENT ID: ABHA NO

AGE/SEX

RECEIVED: 01/07/2023 09:09:51

:34 Years

REPORTED :07/07/2023 07:55:22

**Biological Reference Interval Test Report Status** Results Units <u>Final</u>

#### MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

**XRAY-CHEST** 

BOTH THE LUNG FIELDS ARE CLEAR

BOTH THE COSTOPHRENIC AND CARIOPHRENIC ANGELS ARE CLEAR

BOTH THE HILA ARE NORMAL

CARDIAC AND AORTIC SHADOWS APPEAR NORMAL **»**» BOTH THE DOMES OF THE DIAPHRAM ARE NORMAL >> >>

VISUALIZED BONY THORAX IS NORMAL **»**»

**NORMAL IMPRESSION** 

**ECG** 

**ECG** WITHIN NORMAL LIMITS

**MEDICAL HISTORY** 

RELEVANT PRESENT HISTORY ALLERGY TO DUST RELEVANT PAST HISTORY NOT SIGNIFICANT

RELEVANT PERSONAL HISTORY MARRIED NO CHILD VEG RELEVANT FAMILY HISTORY **NOT SIGNIFICANT** 

JOB OCCUPATIONAL HISTORY

HISTORY OF MEDICATIONS NOT SIGNIFICANT

**ANTHROPOMETRIC DATA & BMI** 

HEIGHT IN METERS 1.67 mts WEIGHT IN KGS. 75.4 Kgs

BMI 27 BMI & Weight Status as follows/sqmts

> Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

**GENERAL EXAMINATION** 

MENTAL / EMOTIONAL STATE **NORMAL** PHYSICAL ATTITUDE **NORMAL HEALTHY** GENERAL APPEARANCE / NUTRITIONAL **STATUS** 

**AVERAGE BUILT / SKELETAL FRAMEWORK NORMAL** FACIAL APPEARANCE SKIN **NORMAL** 

Page 17 Of 20



**PERFORMED AT:** 

Agilus Diagnostics Ltd. E-368, Lgf, Nirman Vihar, Near Nirman Vihar Metro New Delhi, 110092 New Delhi, India

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@agilus.in





CODE/NAME & ADDRESS: C000138361 ACCESSION NO: 0028WG000025 AGE/SEX :34 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 

8800465156

PATIENT ID : PIYUM05018928

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 01/07/2023 09:09:51 REPORTED :07/07/2023 07:55:22

**Biological Reference Interval Test Report Status** Results Units <u>Final</u>

NORMAL UPPER LIMB NORMAI LOWER LIMB **NORMAL NECK** 

NOT ENLARGED OR TENDER NECK LYMPHATICS / SALIVARY GLANDS

**NOT ENLARGED** THYROID GLAND

CAROTID PULSATION **NORMAL TEMPERATURE NORMAL** 

**PULSE** 83/MINUTE, REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO

CAROTID BRUIT

NORMAL RESPIRATORY RATE

**CARDIOVASCULAR SYSTEM** 

BP 145/98 mm/Hg

**NORMAL PERICARDIUM** APEX BEAT NORMAL

**HEART SOUNDS** S1, S2 HEARD NORMALLY

**MURMURS ABSENT** 

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST **NORMAL** MOVEMENTS OF CHEST SYMMETRICAL BREATH SOUNDS INTENSITY **NORMAL** 

**BREATH SOUNDS QUALITY** VESICULAR (NORMAL)

ADDED SOUNDS **ABSENT** 

**PER ABDOMEN** 

**APPEARANCE NORMAL** VENOUS PROMINENCE **ABSENT NOT PALPABLE LIVER** NOT PALPABLE **SPLEEN** 

**CENTRAL NERVOUS SYSTEM** 

NORMAL HIGHER FUNCTIONS CRANIAL NERVES **NORMAL NORMAL** CEREBELLAR FUNCTIONS SENSORY SYSTEM **NORMAL NORMAL** MOTOR SYSTEM

Page 18 Of 20



Agilus Diagnostics Ltd. E-368, Lgf, Nirman Vihar, Near Nirman Vihar Metro New Delhi, 110092 New Delhi, India

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@agilus.in





CODE/NAME & ADDRESS : C000138361 ACCESSION NO : **0028WG000025** AGE/SEX : 34 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PIYUM05018928 DRAWN :

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 01/07/2023 09:09:51

DELHI

NEW DELHI 110030

ABHA NO : RECEIVED : 01/07/2023 09:09:51

REPORTED : 07/07/2023 07:55:22

Test Report Status <u>Final</u> Results Biological Reference Interval Units

REFLEXES NORMAL

MUSCULOSKELETAL SYSTEM

SPINE NORMAL JOINTS NORMAL

BASIC EYE EXAMINATION

CONJUNCTIVA NORMAL EYELIDS NORMAL

EYE MOVEMENTS NORMAL CORNEA NORMAL

DISTANT VISION RIGHT EYE WITH GLASSES NORMAL DISTANT VISION LEFT EYE WITH GLASSES NORMAL

NEAR VISION RIGHT EYE WITH GLASSES NORMAL NEAR VISION LEFT EYE WITH GLASSES NORMAL

COLOUR VISION NORMAL

BASIC ENT EXAMINATION

EXTERNAL EAR CANAL
TYMPANIC MEMBRANE
NORMAL

NOSE NO ABNORMALITY DETECTED

SINUSES NORMAL

THROAT NO ABNORMALITY DETECTED

TONSILS NOT ENLARGED

**SUMMARY** 

RELEVANT HISTORY NOT SIGNIFICANT RELEVANT GP EXAMINATION FINDINGS NOT SIGNIFICANT

RELEVANT LAB INVESTIGATIONS WITHIN NORMAL LIMITS

RELEVANT NON PATHOLOGY DIAGNOSTICS NO ABNORMALITIES DETECTED

REMARKS / RECOMMENDATIONS "NO ABNORMALITY FOUND OUT OF THE DIAGNOSTIC PACKAGE REQUESTED. GENERAL PHYSICAL EXAMINATION IS NORMAL."

"

Page 19 Of 20





View Details

) (; .... D ....

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@agilus.in





**REF. DOCTOR: SELF PATIENT NAME: PIYUSH KUMAR** 

CODE/NAME & ADDRESS: C000138361 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 8800465156

ACCESSION NO: 0028WG000025

PATIENT ID : PIYUM05018928

CLIENT PATIENT ID: ABHA NO

AGE/SEX

RECEIVED: 01/07/2023 09:09:51 REPORTED: 07/07/2023 07:55:22

:34 Years

**Test Report Status** Results Units **Final** 

# MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

**ULTRASOUND ABDOMEN** 

**ULTRASOUND ABDOMEN** 

FATTY CHANGE LIVER WITH LEFT RENEL CALCULUS.

**TMT OR ECHO** 

**TMT OR ECHO** 

MILD CONCENTRIC LVH TRACE TR, TRACE MR.

#### Interpretation(s)

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

\*\*End Of Report\*\* Please visit www.agilusdiagnostics.com for related Test Information for this accession

# **CONDITIONS OF LABORATORY TESTING & REPORTING**

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
  - i. Specimen received is insufficient or inappropriate
  - ii. Specimen quality is unsatisfactory
  - iii. Incorrect specimen type
  - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of gueries please call customer care (91115 91115) within 48 hours of the report.

### **Agilus Diagnostics Ltd**

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Page 20 Of 20





# **PERFORMED AT:**

Agilus Diagnostics Ltd. E-368, Lgf, Nirman Vihar, Near Nirman Vihar Metro New Delhi, 110092 New Delhi, India Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email: wellness.eastdelhi@agilus.in

